Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: Results of the randomised phase IIIb CASIMAS study

Jalid Sehouli, Klaus Pietzner, Pauline Wimberger, Ignace Vergote, Per Rosenberg, Andreas Schneeweiss, Carsten Bokemeyer, Christoph Salat, Giovanni Scambia, Dominique Berton-Rigaud, Armando Santoro, Andrés Cervantes, Olivier Trédan, Christophe Tournigand, Nicoletta Colombo, Alexander S. Dudnichenko, Anneke Westermann, Hilke Friccius-Quecke, Florian Lordick

Research output: Contribution to journalArticlepeer-review

Abstract

This two-arm, randomised, multicentre, openlabel, phase IIIb study investigated the safety and efficacy of a 3-h catumaxomab infusion with/without prednisolone premedication to reduce catumaxomab-related adverse events. Patients with malignant ascites due to epithelial cancer received four 3-h intraperitoneal catumaxomab infusions with/without intravenous prednisolone (25 mg) premedication before each infusion. The primary safety endpoint was a composite safety score calculated from the incidence and intensity of the most frequent catumaxomab-related adverse events (pyrexia, nausea, vomiting and abdominal pain). Puncture-free survival (PuFS) was a coprimary endpoint. Time to next puncture (TTPu) and overall survival (OS) were secondary endpoints. Prednisolone premedication did not result in a significant reduction in the main catumaxomab-related adverse events. The mean composite safety score was comparable in both arms (catumaxomab plus prednisolone, 4.1; catumaxomab, 3.8; p = 0.383). Median PuFS (30 vs. 37 days) and TTPu (78 vs. 102 days) were shorter in the catumaxomab plus prednisolone arm than in the catumaxomab arm, but the differences were not statistically significant (p = 0.402 and 0.599, respectively). Median OS was longer in the catumaxomab plus prednisolone arm than in the catumaxomab arm (124 vs. 86 days), but the difference was not statistically significant (p = 0.186). The superiority of catumaxomab plus prednisolone versus catumaxomab alone could not be proven for the primary endpoint. Prednisolone did not result in a significant reduction in the main catumaxomab-related adverse events. The study confirms the safety and efficacy of catumaxomab administered as four 3-h intraperitoneal infusions for the treatment of malignant ascites.

Original languageEnglish
Article number76
JournalMedical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - 2014

Keywords

  • Catumaxomab
  • Epithelial cancer
  • Malignant ascites
  • Prednisolone
  • Premedication

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Fingerprint

Dive into the research topics of 'Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: Results of the randomised phase IIIb CASIMAS study'. Together they form a unique fingerprint.

Cite this